Clinical Trial Update: A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of stannsoporfin in neonates with hyperbilirubinemia was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperbilirubinemia Neonatal

Drugs mentioned

• stannsoporfin (stannsoporfin)

Snippet

Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | Conditions: Hyperbilirubinemia, Neonatal | Phase 2 | Status: TERMINATED | Results posted: 2014-08-29